The outlook is rosy for the most flexible and adaptable, pharma business leaders agree
This article was originally published in Scrip
Executive Summary
Despite the dreaded patent cliff, spiralling costs of R&D and increasingly demanding regulatory hurdles, big pharma still has opportunities for growth and there remain huge areas of unmet medical need. But adaptability will be key, according to business leaders speaking at the FT Global Pharmaceutical and Biotechnology Conference in London on November 17-18th.